ライフサイエンスコーパス: vein

1 toimmune disease, thrombosis of non-varicose veins).

2 o include bundle sheath cells encircling the vein.

3 (RF) of 7 living donor kidneys via the renal vein.

4 ype identity determined by distance from the vein.

5 ted them into FIX knockout mice via the tail vein.

6 ition and in more distant positions from the vein.

7 administered to the patient via a peripheral vein.

8 alized, cryotherapy-dosing strategy for each vein.

9 cluded femoral arteries and the accompanying vein.

10 ascular deployment into the anterior cardiac vein.

11 reased hydrostatic pressure within the renal vein.

12 of the right femoral artery and left femoral vein.

13 g injection of carcinoma cells into the tail vein.

14 curs when islets are infused into the portal vein.

15 tegrity and muscular damage of the harvested vein.

16 0% HG or 75% HG alone to eliminate reticular veins.

17 , which in turn specify the position of wing veins.

18 elle volume in sheath cells surrounding leaf veins.

19 Time to effect was detected in 72.1% of veins.

20 wed ectatic pulmonary arteries and pulmonary veins.

21 ore abundant in human arteries than in human veins.

22 ety of 2 sclerosants used to treat reticular veins: 0.2% polidocanol diluted in 70% hypertonic glucos

23 h repeated doses of ADHLSCs via a peripheral vein (35 million In-oxine-labeled cells, followed by 125

24 ate gene as it is expressed in the pulmonary veins, a source of AF in many individuals.

25 stula as a late complication after pulmonary vein ablation, leading to septic air emboli and requirin

26 dmitted to hospital 2 months after pulmonary vein ablation.

27 fication of the algorithmic role of tumor in vein and rim arterial phase hyperenhancement improves th

28 We used Drosophila melanogaster wing vein and scutellar bristle development to screen Rab pro

29 m 4 had occluded inferior vena cava or iliac veins and 2 had previous complex vascular reconstruction

30 addition, the oligomer can cross through the veins and enter the apoplastic space in the leaves.

31 OT pathway may coordinate the positioning of veins and stomata in monocot leaves and that distinct me

32 leads to predominate remodeling of pulmonary veins and that the severity of venous remodeling is asso

33 ercitol and starch) in the leaf lamina, main veins and twigs over 24 h.

34 size-invariant units like plant stems, leaf veins and vascular and respiratory systems provide hiera

35 gnificantly for patients with less prominent veins and when the procedure was performed on unfamiliar

36 7.3%) had cavernous transformation of portal vein, and 3 (3.1%) had post-transplant thrombosis.

37 Tracer was injected via the tail vein, and dynamic PET scans were acquired for 90 min, fo

38 re mapping of tumors, hepatic artery, portal vein, and the hepatic veins was developed.

39 o tip, but the distance between each pair of veins, and the cell-types that develop between them, dif

40 vessel members increases from minor to major veins; and phloem conductive area scales isometrically w

41 Here I show that remora cranial veins are highly-modified in comparison to those of othe

42 Reticular veins are subdermal veins located in the lower limbs and

43 t, and qRT-PCR were performed on the outflow vein at 7 and 21 days after AVF creation.

44 erfused with autologous blood via the portal vein at three flow rates (60, 80, 100 mL/min per 100 g o

45 trix scaffold was wrapped around the outflow vein compared to control mice that received no scaffoldi

46 e performance in the Contegra bovine jugular vein conduit.

47 tment of the portal vein-superior mesenteric vein confluence for less than 180 degrees .

48 ore sections because of a more heterogeneous vein coverage across slices.

49 Behaviors covered include vein cutting, trenching, girdling, leaf clipping, and ap

50 Dural cerebral veins (CV) are required for cerebrospinal fluid reabsorp

51 trical stimulation near the murine pulmonary vein demonstrates increased susceptibility to atrial arr

52 n developing leaves, as well as reduced leaf vein density and aberrant placement of free-ending veinl

53 We tested the hypothesis that high vein density in C4 leaves is due to elevated auxin biosy

54 Thus, development of high leaf vein density requires elevated auxin biosynthesis and tr

55 Moreover, auxin content and vein density were increased in loss-of-function mutants

56 High vein density, a distinctive trait of C4 leaves, is centr

57 displaying abnormal leaf development/number, vein-derived leaf emergence, and a thick, faciated stem.

58 held that the density and placement of these veins determines maximum leaf hydraulic capacity and thu

59 d the whole-transcriptome in human umbilical vein ECs (HUVECs) and found that ALK1 signaling inhibiti

60 erations in Ca(2+) levels in human umbilical vein endothelial cells (HUVEC) following FXa-mediated PA

61 Human umbilical vein endothelial cells (HUVEC) grown on laminar-flow per

62 chymal stem cells (MSCs) and human umbilical vein endothelial cells (HUVECs) as previously reported.

63 Human umbilical vein endothelial cells (HUVECs) grown in microfluidic de

64 on and oxidant generation in human umbilical vein endothelial cells (HUVECs) obtained from extremely

65 2 vector plasmid-transfected human umbilical vein endothelial cells (HUVECs) resembling EndoMT were m

66 We treated human umbilical vein endothelial cells (HUVECs) with E2, TNFalpha, or bo

67 human dental pulp cells, and human umbilical vein endothelial cells (recell-dTBs); 3) dTBs seeded wit

68 ncreased (18)F-FDG uptake by human umbilical vein endothelial cells in a concentration-dependent mann

69 d reduced ROS productions in human umbilical vein endothelial cells incubated with H2O2 for 2 hours,

70 properdin to the surface of human umbilical vein endothelial cells or Neisseria meningitidis after i

71 l as increasing adherence of human umbilical vein endothelial cells to the active peptide.

72 vitro when beads coated with human umbilical vein endothelial cells were placed at one end of the mic

73 cule-1) expression on HUVEC (human umbilical vein endothelial cells) in vitro.

74 elial cell line hCMEC/D3 and human umbilical vein endothelial cells), and without interference of the

75 In human umbilical vein endothelial cells, IL-1beta treatment directly enha

76 formation when expressed in human umbilical vein endothelial cells.

77 matin immunoprecipitation in human umbilical vein endothelial cells.

78 increased adiponectin expression compared to vein exposed to fat alone.

79 External jugular vein exposed to fat incorporated with PGZ had increased

80 o investigate the effect of change in portal vein flow rates on the size and shape of ablations creat

81 nitial imaging and extensive portomesenteric vein gas on follow-up imaging.

82 , intestinal intramural gas, portomesenteric vein gas, extensive intraperitoneal gas and intraabdomin

83 following BAT with extensive portomesenteric vein gas.

84 bolic protection devices (EPD) for saphenous vein graft (SVG) intervention; however, studies have sho

85 respectively, restenosis after angioplasty, vein graft intimal thickening and atherogenesis.

86 In contrast, saphenous vein graft patency declined over time and similarly in p

87 ous coronary intervention (PCI) of saphenous vein grafts (SVGs) has historically been associated with

88 h an internal mammary artery and with 1 to 4 vein grafts were recruited.

89 cic artery (ITA) grafts and 20,066 saphenous vein grafts.

90 onsensus statements maintain that endoscopic vein harvesting (EVH) should be standard care in coronar

91 tunnel CO2 EVH (n=100), and traditional open vein harvesting (n=100) groups.

92 The open vein harvesting group demonstrated marginally better end

93 .003) for open tunnel EVH compared with open vein harvesting.

94 optimal results comparable to those of open vein harvesting.

95 VH, 19% for open tunnel EVH, and 6% for open vein harvesting.

96 closed tunnel EVH, open tunnel EVH, and open vein harvesting; P<0.001).

97 Interestingly, however, research in this vein has focused nearly exclusively on just one possible

98 cumulative manner in ex vivo human saphenous vein (HSV) model.

99 Portal vein hypertension (PVH) in liver cirrhosis complicated w

100 practice of applying the tourniquet prior to vein identification and releasing it after sample tubes

101 actors required for induction of the L2 wing vein in Drosophila.

102 resent the results of U-Th dating of calcite veins in the Loma Blanca normal fault zone, Rio Grande r

103 apy is the treatment of choice for reticular veins in the lower limbs, no consensus has been reached

104 he peripheral retina, anterior to the vortex veins, in 21.8% of eyes.

105 tepwise increments of intravenously (jugular vein) infused ammonia is almost totally dependent on GS

106 Pulmonary embolism was induced by jugular vein infusion of (125)I-fibrin or fluorescein isothiocya

107 umber in living mice was assessed after tail vein injection (150 mug of each conjugate per mouse) at

108 lood-brain barrier, to access brain via tail vein injection in mice.

109 was performed by administering a single tail vein injection of (177)Lu-PSMA-617 at different formulat

110 yocardial infarction were randomized to tail-vein injection of 2x10(6) MSCs, with injection repeated

111 etastasis assay we detail here includes tail-vein injection of cancer cells into the mouse and determ

112 Tail vein injection of human endothelial specific Ulex europa

113 Hydrodynamic tail-vein injection of MAN2A1-FER resulted in rapid developme

114 r control Cas9 vector, via hydrodynamic tail vein injection to livers of 8-week-old female FVB/N mice

115 ic gene transfer following hydrodynamic tail vein injection using the kidney-specific podocin and gam

116 dministering an insulin stimulation via tail vein injection.

117 n of 42.1 +/- 3.9 MBq of (18)F-FMISO by tail vein injection.

118 y transferred to recipient mice through tail vein injection.

119 colonization into lung and liver after tail vein injection.

120 ith hepatic deletion of PTEN were given tail-vein injections of MAN2A1-FER.

121 phaS pathology in M83 mice than i.p. or tail vein injections.

122 sess thrombus age in patients with saphenous vein insufficiency treated with sclerotherapy.

123 We classified calf vein into into four main types.

124 aggrecan synthesis was induced on grafting a vein into the arterial circulation, suggesting an import

125 In angiosperms, a complex network of veins irrigates the leaf, and it is widely held that the

126 apy during cryoballoon ablation of pulmonary veins is still unclear.

127 Pulmonary vein isolation (PVI) is a recommended treatment for pati

128 ths; Q1-Q3, 7-36 months) underwent pulmonary vein isolation and completed the entire follow-up.

129 success and low complication rate, pulmonary vein isolation is expected to be increasingly performed

130 Pulmonary vein isolation is the cornerstone of ablation for persis

131 n was performed by circumferential pulmonary vein isolation plus linear ablation of extrapulmonary ro

132 LB) with wide-area circumferential pulmonary vein isolation using irrigated radiofrequency current (R

133 n and fistula are complications of pulmonary vein isolation using thermal energy sources.

134 rdial thoracoscopic radiofrequency pulmonary vein isolation, linear ablation, Marshal ligament disrup

135 In CF-guided pulmonary vein isolation, PVR is explained by lack of both lesion

136 on after contact force (CF)-guided pulmonary vein isolation.

137 tional ablation approach was used (pulmonary vein isolation/stepwise approach).

138 pericardium, and site and size of the great veins (IVC and SVC).

139 were measured 15-20 mm caudal to the hepatic vein junction and recorded by bidimensional imaging on a

140 Reduction of the POU domain TF Ventral veins lacking (Vvl) largely ameliorates the airway morph

141 as well as penetrating cortical arteries and veins lasting several minutes, and gradually recovering

142 techniques affect the integrity of different vein layers, albeit only slightly.

143 fter extended partial hepatectomy and portal vein ligation for multiple bilobar CRLM were applied to

144 nt in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) occurred ov

145 eration after partial hepatectomy and portal vein ligation, and increased the expression of cell cycl

146 Reticular veins are subdermal veins located in the lower limbs and are mainly associat

147 g pressure-regulated distension, a non-toxic vein marker, and graft storage in buffered PlasmaLyte so

148 on thrombotic total occlusion of main portal vein (MPV).

149 ncrease in leukocyte rolling and adhesion in veins near the optic nerve (ON) head at 9 hours after ON

150 However, leaves with reticulate vein networks required more sections because of a more h

151 flux transporter lax2 mutants showed reduced vein numbers.

152 yes demonstrated obvious findings of retinal vein obstruction (5 with central and 2 with hemicentral

153 o outflow obstruction from a central retinal vein obstruction appears to be the most common cause of

154 on (typically central or hemicentral retinal vein obstruction) using en face optical coherence tomogr

155 cular oedema (DME) or branch/central retinal vein occlusion (B/CRVO).

156 nal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular edema (ME).

157 to macular edema secondary to branch retinal vein occlusion (BRVO).

158 cular edema (ME) secondary to branch retinal vein occlusion (BRVO).

159 iography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein occlusion

160 the definition of ischaemic central retinal vein occlusion (CRVO) and stratify the risk of neovascul

161 h macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRV

162 nal (BRVO), hemi-retinal and central retinal vein occlusion (CRVO).

163 retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) in the Study of COmparative Treatm

164 .5), diabetic retinopathy (RR 13.1), retinal vein occlusion (RR 12.9), macular hole (RR 7.7), and epi

165 valence, pattern and risk factors of retinal vein occlusion (RVO) in an elderly population of Nepal.

166 ), diabetic macular edema (DME), and retinal vein occlusion (RVO) were evaluated by Pearson correlati

167 including diabetic retinopathy (DR), retinal vein occlusion (RVO), and neovascular-age related macula

168 d visual acuity (VA) associated with retinal vein occlusion (RVO).

169 tic macular edema (DME, n = 400), or retinal vein occlusion (RVO, n = 400) acquired with Zeiss Cirrus

170 n Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE) study who received either a s

171 Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2); evaluate the baseline relatio

172 re) and similar to patients in other retinal vein occlusion clinical trials.

173 vein occlusions (both <0.1 per 1000 retinal vein occlusion patients in 2011, 5.6 and 140.2 in 2015).

174 ce populations and patients in other retinal vein occlusion trials.

175 edema due to central retinal or hemiretinal vein occlusion who were randomized 1:1 to receive aflibe

176 with central and 2 with hemicentral retinal vein occlusion), 4 eyes were unremarkable at presentatio

177 oea, myocardial infarction, pyrexia, retinal vein occlusion, n=1 each; placebo: vomiting, white blood

178 secondary to central retinal or hemiretinal vein occlusion.

179 ment of macular edema due to central retinal vein occlusion.

180 s with diabetic retinal diseases and retinal vein occlusions (both <0.1 per 1000 retinal vein occlusi

181 Retinal vein occlusions were further divided into branch retinal

182 diabetic retinopathy), 8.3% to treat retinal vein occlusions, and 12.9% for all other uses.

183 ed macular degeneration, and central retinal vein occlusions.

184 neointimal hyperplasia (VNH) at the outflow vein of hemodialysis AVF is a major factor contributing

185 Enhancement of the vein of Labbe, sphenoparietal sinus, and superficial mid

186 parenchyma (PP) transfer cells (TCs) in leaf veins of Arabidopsis (Arabidopsis thaliana) represents a

187 Following intravenous injection in the tail veins of homozygous M83 transgenic (M83(+/+)) mice, robu

188 RNAs against PPP1R1, injected into the tail veins of immune-compromised mice, and followed by noninv

189 deploy E-AB sensors directly in situ in the veins of live animals, achieving micromolar precision ov

190 siella pneumoniae was injected into the tail veins of rats and followed with multiple doses of predat

191 Whereas Ce was found mostly in the leaf veins of the CeO2(-) NP exposed plant, Ce was found in c

192 unsuspected partial thrombus in the splenic vein on imaging.

193 Finally, the presence of hypodense veins on T2* -based MRI.

194 ebral artery stroke with absence of cortical vein opacification in the affected hemisphere (COVES = 0

195 re was calculated, resulting in the cortical vein opacification score (COVES) (range, 0-6).

196 8 nm or 650 nm, where PUT selectively shrank veins or occluded arteries.

197 tely adjacent to major hepatic veins, portal veins, or both; thus, they were not considered suitable

198 ns; the sum of the conductive areas for each vein order increases exponentially from major to minor v

199 how embolisms spread throughout petioles and vein orders during leaf dehydration in relation to condu

200 ically with respect to xylem area across all vein orders.

201 roposed that the AtPIN1 organ initiation and vein patterning functions are split between the SoPIN1 a

202 Pulmonary vein (PV) and peripheral vein (Pe) blood specimens from patients with lung cancer

203 ding abdominal aorta) and catheters (jugular vein, peritoneal cavity, and distal abdominal aorta).

204 and -29 promoter activity is robust in leaf veins, petioles, stems, and vascular tissues and induced

205 Wing vein phenotypes resulting from these trans-species enhan

206 on minor adverse event, with a 3.53% treated-vein pigmentation length for group 1 and 7.09% for group

207 clot formation rate, associated with portal vein platelet aggregates and reductions in protein C, pr

208 ocated immediately adjacent to major hepatic veins, portal veins, or both; thus, they were not consid

209 (CRM) required for kni expression in the L2 vein primordium.

210 e standardised across locations and that the vein prominence of different patient groups is considere

211 Equipment layout on wards and patient vein prominence were identified as the two most importan

212 Pulmonary vein (PV) and peripheral vein (Pe) blood specimens from

213 islet dose (150 islets), or into the portal vein (PV) at a full dose (500 islets).

214 l performance of this catheter for pulmonary vein (PV) isolation.

215 nce of arrhythmia recurrence after pulmonary vein (PV) isolation.

216 ntrant driver regions included the pulmonary vein (PV) regions and inferoposterior left atrial wall.

217 in coronary artery bypass graft surgery, but vein quality and clinical outcomes have been questioned.

218 t the flanks of underlying longitudinal leaf veins, rather than directly above or below.

219 Pulmonary vein reconnection (PVR) still determines recurrences of

220 extrinsic compression of hepatic and portal veins, resulting in functional Budd-Chiari syndrome and

221 plain how impaired iron localization in leaf veins results in incorrect signals of iron sufficiency b

222 s are strap-shaped with a series of parallel veins running from base to tip, but the distance between

223 nal computed tomography scanning and adrenal vein sampling, using strict criteria to define successfu

224 on with treatment according to full cortical vein score and different dichotomized cutoff points was

225 (at least 5 cm in a supragenual superficial-vein segment) and at least one additional risk factor (o

226 mages for two new signs, superior mesenteric vein (SMV) "beaking" and "criss-cross" of the mesenteric

227 x 2.1 cm in size with abutment of the portal vein-superior mesenteric vein confluence for less than 1

228 In this vein, the Cu-catalyzed enantioselective conjugate alkyny

229 In patients with 1 and/or 2 thrombosed veins, the mean PI was 6.03+/-0.54 on the side of cDVT a

230 onductive areas increase from minor to major veins; the sum of the conductive areas for each vein ord

231 increases exponentially from major to minor veins; the volume of individual sieve tube and vessel me

232 possibly associated with TRF-budesonide-deep vein thrombosis (16 mg/day) and unexplained deterioratio

233 RATIONALE: Deep vein thrombosis (DVT) and its complication pulmonary emb

234 Deep vein thrombosis (DVT) and pulmonary embolism are collect

235 Deep vein thrombosis (DVT) with its major complication, pulmo

236 l clot properties can predict recurrent deep vein thrombosis (DVT), we studied 320 consecutive patien

237 as a complimentary approach to isolated calf vein thrombosis (DVT).

238 erse events (n = 7), cataracts (n = 4), deep vein thrombosis (n = 3), cerebral infarction (n = 2), he

239 P = 0.007), disability (P = 0.012), and deep vein thrombosis (P = 0.048).

240 e hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with (90)Y radioembolizati

241 offer patients with symptomatic superficial-vein thrombosis a less burdensome and less expensive ora

242 ficacy outcomes in patients with superficial-vein thrombosis and additional risk factors given either

243 venous thromboembolism (which includes deep vein thrombosis and pulmonary embolism), but the evidenc

244 Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism.

245 artery on the same side as the isolated calf vein thrombosis as well as on the opposite side.

246 Superficial-vein thrombosis can lead to deep-vein thrombosis and pul

247 ntly develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant the

248 years or older with symptomatic superficial-vein thrombosis from 27 sites (academic, community hospi

249 to fondaparinux for treatment of superficial-vein thrombosis in terms of symptomatic deep-vein thromb

250 ics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis included patients aged 65 years or older

251 In contrast, in a model of vein thrombosis induced by flow restriction in the infer

252 Deep vein thrombosis occurred in 5 patients.

253 dependent of the presence or absence of deep vein thrombosis or pulmonary embolism at the time of IVC

254 vein thrombosis in terms of symptomatic deep-vein thrombosis or pulmonary embolism, progression or re

255 outcome was a composite of symptomatic deep-vein thrombosis or pulmonary embolism, progression or re

256 gement, neurology consultation, Holter, deep vein thrombosis prophylaxis, oral hypoglycemic intensifi

257 lly, complications (pulmonary embolism, deep vein thrombosis, acute respiratory distress syndrome, pn

258 tors of PE (obesity, pregnancy, cancer, deep vein thrombosis, major procedure, spinal cord paralysis,

259 statin use with venous thromboembolism, deep vein thrombosis, or pulmonary embolism in adults were in

260 llected data on venous thromboembolism, deep vein thrombosis, or pulmonary embolism outcomes.

261 l complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia).

262 served in rates of postoperative ileus, deep vein thrombosis, small bowel obstruction, urinary strict

263 Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical cath

264 unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.

265 eminated tuberculosis complicated by splenic vein thrombosis.

266 % mortality, 43.7% disability, and 9.8% deep vein thrombosis.

267 sm, progression or recurrence of superficial vein-thrombosis, and all-cause mortality at 45 days in t

268 sm, progression or recurrence of superficial vein-thrombosis, and all-cause mortality, and was not as

269 a-miR-135a-3p expression with inosine in the vein tissue, while miR-216a-5p, conversely, was correlat

270 ich we show is restricted to developing leaf veins, to include bundle sheath cells encircling the vei

271 ell density and proliferation in the outflow veins treated with CorMatrix compared to controls (P < 0

272 In conclusion, outflow veins treated with CorMatrix have reduced VNH.

273 In outflow veins treated with CorMatrix, there was an increase in t

274 system and subsequently develop into portal vein tumour thrombosis (PVTT).

275 M), macrovascular involvement of all hepatic veins (V) or portal bifurcation (P), contiguous extrahep

276 Tumor in vein was a common finding in patients with non-HCC malig

277 he carotid artery to the ipsilateral jugular vein was connected to create an AVF, and CorMatrix scaff

278 ietal sinus, and superficial middle cerebral vein was graded by one neuroradiologist, as follows: 0,

279 tween carotid artery and ipsilateral jugular vein was used to assess effects of PGZ/fat depots on vas

280 hepatic artery, portal vein, and the hepatic veins was developed.

281 eal artery and the number of thrombosed calf veins was investigated.

282 water, but 40% lower on delta(18) O of main vein water.

283 In this vein, we report an analogue of boranthrene (9,10-diboraa

284 In this vein, we report the synthesis, structure determination,

285 depots transplanted perivascular to jugular vein were assessed by HPLC/MS/MS, and retention of the f

286 Patients with thrombosis of any other vein were excluded.

287 Pulmonary veins were assessed for PAPVR or TAPVR, PDA, cardiac ape

288 All veins were harvested by a single experienced practitione

289 The reticular veins were measured on images obtained before treatment

290 ion of sensors small enough to insert into a vein, which, for the rat animal model we employ, entails

291 y of 180-second cryoballoon applications per vein with a bonus freeze (control group, n=70) or to a s

292 An increased calibre of the splenic vein with a hyperechogenicity within it raised the suspi

293 18 to 69 years, who had at least 1 reticular vein with a minimum length of 10 cm in 1 of their lower

294 sign, connecting the left inferior pulmonary vein with the mitral annulus.

295 rior to 75% HG alone in sclerosing reticular veins, with no statistical difference for complications.

296 As on the pinna surface in the proximity of veins, with the majority localized near the midrib.

297 point was the disappearance of the reticular veins within 60 days after treatment with sclerotherapy.

298 Increased vulnerability in the higher order veins would also be consistent with these experiencing t

299 gor loss point, only small fractions of leaf vein xylem conduits were embolized, and substantial xyle

300 the decline of Kleaf to embolism in the leaf vein xylem.